Goldman Sachs Upgrades Emergent BioSolutions (EBS) to Buy
Goldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions (NYSE: EBS) from Neutral to Buy with a price target of $75.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)